Jefferson University Hospitals

Physician Profile

Wm. Kevin Kelly, DO

Academic Title: Professor

Specialties
Medical Oncology
Medical Oncology - Bladder Cancer
Medical Oncology - Kidney Cancer
Medical Oncology - Prostate Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 320A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 503-7697

Medical Services

Board Certifications

  • Medical Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Education

  • Philadelphia College of Osteopathic Medicine, Medical School

Internship

  • St Joseph's Hospital

Residency

  • Albert Einstein Medical Center, Philadelphia, PA

Fellowship

  • Weill Cornell Medical Center - New York Presbyterian Hospital
  • Memorial Hospital for Cancer & Allied Disease

Recent Publications

Effect of docetaxel on safety and efficacy of radium-223

Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray

Targeting epigenetics for the treatment of prostate cancer: Recent progress and future directions

Prostate cancer biomarker: A key field to explore

C-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

Targeting Angiogenesis as a Promising Modality for the Treatment of Prostate Cancer

An internet intervention for management of uncertainty during active surveillance for prostate cancer

New therapies for castration-resistant prostate cancer: Efficacy and safety

Epothilones in prostate cancer

Genome-wide methylation analysis identifies involvement of TNF-α mediated cancer pathways in prostate cancer

The needs for men undergoing active surveillance (AS) for prostate cancer: Results of a focus group study

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of seven prospective clinical trials

Redefining hormone resistance in prostate cancer

Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy

Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus doxorubicin in the treatment of metastatic castration-resistant prostate cancer

Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer

Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer

TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortality

An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer